

Luca Massacesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/39940/publications.pdf>

Version: 2024-02-01

117
papers

5,432
citations

76326

40
h-index

88630

70
g-index

120
all docs

120
docs citations

120
times ranked

6018
citing authors

#	ARTICLE	IF	CITATIONS
1	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. <i>Nature Reviews Neurology</i> , 2016, 12, 714-722.	10.1	274
2	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	10.2	238
3	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 189-199.	10.2	210
4	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006, 12, 814-823.	3.0	206
5	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.1	201
6	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 459.	9.0	199
7	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. <i>Annals of Neurology</i> , 2018, 83, 283-294.	5.3	160
8	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. <i>Neurology</i> , 2001, 57, 62-68.	1.1	156
9	Histopathological Characterization of Magnetic Resonance Imaging-Detectable Brain White Matter Lesions in a Primate Model of Multiple Sclerosis. <i>American Journal of Pathology</i> , 1998, 153, 649-663.	3.8	145
10	Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. <i>Annals of Neurology</i> , 2011, 70, 22-29.	5.3	137
11	Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. <i>Annals of Neurology</i> , 1995, 37, 519-530.	5.3	132
12	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842.	3.0	115
13	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009, 256, 1891-1898.	3.6	112
14	The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine. <i>Annals of Neurology</i> , 1991, 29, 542-547.	5.3	108
15	Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. <i>Lupus</i> , 1999, 8, 11-19.	1.6	108
16	A new primate model for multiple sclerosis in the common marmoset. <i>Trends in Immunology</i> , 2000, 21, 290-297.	7.5	108
17	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
18	Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. <i>Neuroscience</i> , 2001, 102, 687-695.	2.3	98

#	ARTICLE	IF	CITATIONS
19	The formation of inflammatory demyelinated lesions in cerebral white matter. <i>Annals of Neurology</i> , 2014, 76, 594-608.	5.3	89
20	In healthy primates, circulating autoreactive T cells mediate autoimmune disease.. <i>Journal of Clinical Investigation</i> , 1994, 94, 1339-1345.	8.2	89
21	Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (<i>Callithrix</i>) Tj ETQq1 1 0.784314 rgBT / Overlock 10	2.3	83
22	Inhibition of Immune Synapse by Altered Dendritic Cell Actin Distribution: A New Pathway of Mesenchymal Stem Cell Immune Regulation. <i>Journal of Immunology</i> , 2010, 185, 5102-5110.	0.8	78
23	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 184, 41-49.	0.6	74
24	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	2.3	71
25	A genome screen for multiple sclerosis in Italian families. <i>Genes and Immunity</i> , 2001, 2, 205-210.	4.1	70
26	Transforming growth factor- β 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. <i>Journal of Neuroscience Research</i> , 1995, 40, 127-133.	2.9	68
27	HLA-DRB1*03:01 multiple sclerosis association in Continental Italy and correlation with disease prevalence in Europe. <i>Journal of Neuroimmunology</i> , 2004, 150, 178-185.	2.3	66
28	Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 35.	9.0	65
29	Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2018, 9, 981.	2.4	64
30	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	1.9	59
31	Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 50, 486-493.	5.3	58
32	Clinical, Pathological, and Immunologic Aspects of the Multiple Sclerosis Model in Common Marmosets (<i>Callithrix jacchus</i>). <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 341-355.	1.7	58
33	A Key Role for Poly(ADP-Ribose) Polymerase-1 Activity during Human Dendritic Cell Maturation. <i>Journal of Immunology</i> , 2007, 179, 305-312.	0.8	57
34	Carbon Nanotube Scaffolds Instruct Human Dendritic Cells: Modulating Immune Responses by Contacts at the Nanoscale. <i>Nano Letters</i> , 2013, 13, 6098-6105.	9.1	54
35	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1068-1070.	3.0	53
36	Combined treatment with atorvastatin and minocycline suppresses severity of EAE. <i>Experimental Neurology</i> , 2008, 211, 214-226.	4.1	49

#	ARTICLE	IF	CITATIONS
37	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	1.8	47
38	Suppression of experimental allergic encephalomyelitis by retinoic acid. <i>Journal of the Neurological Sciences</i> , 1987, 80, 55-64.	0.6	45
39	Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging. <i>Archives of Neurology</i> , 2005, 62, 1843.	4.5	45
40	The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 421-432.	3.0	44
41	A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 167-172.	2.2	40
42	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. <i>European Journal of Human Genetics</i> , 1999, 7, 377-385.	2.8	38
43	Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. <i>Neuroscience Letters</i> , 2000, 296, 174-176.	2.1	37
44	Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial. <i>PLoS ONE</i> , 2014, 9, e113371.	2.5	37
45	IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001, 121, 111-119.	2.3	36
46	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	36
47	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. <i>Human Immunology</i> , 2003, 64, 274-284.	2.4	34
48	Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 974-981.	1.9	34
49	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
50	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. <i>Journal of Neurology</i> , 2020, 267, 3343-3353.	3.6	34
51	T-cell autoimmunity in multiple sclerosis. <i>Trends in Immunology</i> , 1995, 16, 259-261.	7.5	33
52	Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. <i>Neuroscience Letters</i> , 2002, 328, 325-327.	2.1	33
53	Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. <i>Epilepsia</i> , 2021, 62, 2159-2170.	5.1	31
54	HLA A2 allele is associated with age at onset of Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 45, 397-400.	5.3	29

#	ARTICLE	IF	CITATIONS
55	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. <i>Journal of Neuroimmunology</i> , 2006, 179, 108-116.	2.3	29
56	Development and Psychometric Properties of a Neuropsychological Battery for Mild Cognitive Impairment with Small Vessel Disease: The VMCI-Tuscany Study. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1313-1323.	2.6	29
57	Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. <i>European Journal of Neurology</i> , 2020, 27, 633-643.	3.3	29
58	Detection of skewed T-cell receptor V β 2 gene usage in the peripheral blood of patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1998, 85, 22-32.	2.3	28
59	Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA/6-MP. <i>Journal of Neuroimmunology</i> , 2010, 218, 28-35.	2.3	25
60	Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. <i>Multiple Sclerosis Journal</i> , 2014, 20, 64-71.	3.0	25
61	Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. <i>Journal of NeuroVirology</i> , 2015, 21, 666-670.	2.1	25
62	The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 559.	4.8	25
63	Rhein and derivatives. In vitro studies on their capacity to inhibit certain proteases. <i>Pharmacological Research Communications</i> , 1982, 14, 103-112.	0.2	23
64	Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 624-630.	3.3	21
65	Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1993, 44, 69-75.	2.3	20
66	Fas Gene Polymorphisms Are Not Associated With Systemic Lupus Erythematosus, Multiple Sclerosis And Hiv Infection. <i>Disease Markers</i> , 1998, 13, 221-225.	1.3	20
67	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. <i>Genes and Immunity</i> , 2008, 9, 7-15.	4.1	20
68	Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 183.	1.6	19
69	Predictors of response to opicinumab in acute optic neuritis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1154-1162.	3.7	19
70	Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS. <i>Journal of Neuroimmunology</i> , 2002, 127, 149-159.	2.3	18
71	TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood. <i>EBioMedicine</i> , 2021, 68, 103429.	6.1	18
72	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. <i>Journal of the Neurological Sciences</i> , 1993, 119, 91-98.	0.6	17

#	ARTICLE	IF	CITATIONS
73	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. <i>Journal of Neuroimmunology</i> , 2003, 143, 97-100.	2.3	17
74	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005, 26, s200-s203.	1.9	17
75	Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 61-70.	3.0	16
76	Segregation of immunoglobulin heavy chain constant region genes in multiple sclerosis sibling pairs. <i>Journal of Neuroimmunology</i> , 1993, 42, 113-116.	2.3	15
77	Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset. <i>Journal of Neuroimmunology</i> , 2017, 304, 86-92.	2.3	15
78	T-cell response to myelin basic protein and lipid-bound myelin basic protein in patients with multiple sclerosis and healthy donors. <i>Journal of Neuroimmunology</i> , 1998, 82, 96-100.	2.3	14
79	Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells. , 2000, 59, 86-93.		14
80	Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. <i>Clinical Neurology and Neurosurgery</i> , 2002, 104, 177-181.	1.4	14
81	SWI enhances vein detection using gadolinium in multiple sclerosis. <i>Acta Radiologica Open</i> , 2015, 4, 204798161456093.	0.6	14
82	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). <i>Neurological Sciences</i> , 2017, 38, 231-236.	1.9	14
83	Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 24-26.	2.0	14
84	Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1708-1718.	3.3	14
85	Short-term evolution of autoreactive T cell repertoire in multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2001, 66, 517-524.	2.9	13
86	DNA Changes in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis. <i>Journal of Neurochemistry</i> , 1984, 43, 1635-1641.	3.9	12
87	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 143, 31-38.	2.3	12
88	No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1188-1192.	3.0	11
89	Immunosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. <i>Immunopharmacology</i> , 1997, 37, 191-197.	2.0	10
90	Multiple sclerosis and Type I diabetes. <i>Diabetologia</i> , 2002, 45, 1735-1736.	6.3	9

#	ARTICLE	IF	CITATIONS
91	Use of technetium-99m hexamethylpropylene amine oxime SPET for the study of cerebral blood flow reactivity after acetazolamide infusion in patients with Behçet's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 700-706.	6.4	8
92	Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 767-772.	1.9	8
93	Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 650-658.	3.7	8
94	Neurology and the COVID-19 emergency. <i>Neurological Sciences</i> , 2020, 41, 1343-1344.	1.9	8
95	Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102591.	2.0	8
96	Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2005, 168, 111-117.	2.3	7
97	Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e58.	6.0	6
98	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2021, 27, 706-711.	3.0	6
99	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 820256.	2.4	6
100	Lysosomal enzymes in experimental allergic encephalomyelitis: Time course and evidence of the source. <i>Neurochemical Research</i> , 1988, 13, 165-169.	3.3	5
101	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	1.4	4
102	Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1851-1854.	3.9	4
103	Palmitoyl Derivatives of GpMBP Epitopes: T-Cell Response and Peptidases Susceptibility. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3504-3510.	6.4	3
104	Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103679.	2.0	3
105	Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP Astrocytopathy. <i>Neurology</i> , 2022, 98, 720-722.	1.1	3
106	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 51-59.	0.1	1
107	Synthesis of lipopeptides of the immunodominant epitope hMBP(83-99) containing amide or C-C bond linked hydrophobic chains for the study of T cell response. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 51-59.	0.1	1
108	Corrigendum to "Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans" [J. Neuroimmunol. 179 (2006) 108-116]. <i>Journal of Neuroimmunology</i> , 2007, 189, 175-176.	2.3	1

#	ARTICLE	IF	CITATIONS
109	Efficacy for remyelination and safety of anti-lingo-1 monoclonal antibody (biib033) in acute optic neuritis: results from the renew study. <i>Journal of the Neurological Sciences</i> , 2015, 357, e14-e15.	0.6	1
110	A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet. <i>Intractable and Rare Diseases Research</i> , 2019, 8, 275-278.	0.9	1
111	Association of celiac disease in patients with multiple sclerosis in Tuscany. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 474-476.	0.3	1
112	Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance. <i>Neurological Sciences</i> , 2022, , 1.	1.9	1
113	Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
114	Response: Brightening the crystal ball: A constructive reappraisal of the postwithdrawal seizure relapse prediction model. <i>Epilepsia</i> , 2021, 62, 3148-3149.	5.1	0
115	Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Reactivation In Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Severe Multiple Sclerosis (MS).. <i>Blood</i> , 2010, 116, 4537-4537.	1.4	0
116	Lipophilic modifications of peptide epitopes: T-cell response and susceptibility to peptidases. , 2002, , 697-699.		0
117	Recombinant MOG from baculovirus inhibits anti-hMOG(30-50) antibodies detected by the synthetic antigen [Asn31(Glc)]hMOG(30-50). , 2002, , 708-709.		0